cetrelimab (JNJ-63723283) / J&J 
Welcome,         Profile    Billing    Logout  
 0 Diseases   11 Trials   11 Trials   106 News 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cetrelimab (JNJ-63723283) / J&J
2020-004506-64: A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

Ongoing
3
1050
Europe
TAR-200, Cetrelimab, Vesiculture, JNJ-17000139, JNJ-63723283, Tablet, Powder for solution for infusion, Powder for bladder irrigation, Vesiculture, powder for bladder irrigation
Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & development LLC, Janssen Research & Development LLC, Janssen-Cilag SpA, Janssen-cilag international NV
BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer, Bladder cancer, Diseases [C] - Cancer [C04]
 
 
SunRISe-2, NCT04658862 / 2020-002620-36: A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

Active, not recruiting
3
518
Europe, Canada, Japan, US, RoW
Cetrelimab, JNJ-63723283, TAR-200, JNJ-17000139, Cisplatin, Gemcitabine, Conventional radiation therapy, Hypo-fractioned radiation therapy
Janssen Research & Development, LLC, Janssen Research & Development LLC
Urinary Bladder Neoplasms
12/26
12/29
SunRISe-3, NCT05714202 / 2020-004506-64: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

Active, not recruiting
3
1135
Europe, Canada, Japan, US, RoW
TAR-200, JNJ-17000139, Cetrelimab, JNJ-63723283, BCG Vesiculture
Janssen Research & Development, LLC, Janssen Research & development LLC, Janssen Research & Development LLC, Janssen-Cilag SpA, Janssen-cilag international NV
Bladder Cancer
09/29
09/29
2020-005565-13: A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy Estudio de fase 2, multicéntrico, aleatorizado y abierto, de TAR-200 en combinación con cetrelimab y monoterapia con cetrelimab en participantes con carcinoma urotelial de vejiga músculo-invasivo que se vayan a tratar con cistectomía radical y no sean elegibles o rechacen recibir tratamiento con quimioterapia neoadyuvante basada en platino

Ongoing
2
160
Europe
TAR-200, Cetrelimab, JNJ-17000139, JNJ-63723283, Tablet, Lyophilisate for solution for infusion
Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development LLC
Muscle-Invasive Urothelial Carcinoma of the Bladder Carcinoma urotelial de vejiga músculo-invasivo, Bladder cancer Cáncer de vejiga, Diseases [C] - Cancer [C04]
 
 
2022-002586-15: Erdafitinib (ERDA) alone or in combination with cetrelimab (CET) as neoadjuvant treatment (prior to surgery) in subjects with muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations and are ineligible for receiving cisplatin treatment Erdafitinib (ERDA) solo o en combinación con cetrelimab (CET) como tratamiento neoadyuvante (antes de la cirugía) en sujetos con cáncer de vejiga músculo-invasivo cuyos tumores expresan alteraciones del gen FGFR y no son elegibles para recibir tratamiento con cisplatino

Not yet recruiting
2
90
Europe
Cetrelimab, Erdafitinib, JNJ-63723283, JNJ-42756493, Solution for infusion, Tablet, Balversa
Spanish Oncology Genito Urinary Group (SOGUG), Spanish Oncology Genitourinary Group (SOGUG), Janssen Pharmaceutica NV
Muscle-invasive bladder cancer (MIBC) Cáncer de vejiga con invasión muscular, Bladder cancer that spreads beyond the inner lining of the bladder and into the muscle layer Cáncer de vejiga que se propaga al musculo grueso, Diseases [C] - Cancer [C04]
 
 
SOGUG-NEOWIN, NCT06511648 / 2022-002586-15: Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Recruiting
2
90
Europe
Erdafitinib monotherapy, Cetrelimab and Erdafitinib combination
Spanish Oncology Genito-Urinary Group, Janssen-Cilag Ltd., Pivotal S.L.
Muscle-invasive Bladder Cancer
03/26
03/29
SunRISe-4, NCT04919512 / 2020-005565-13: A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

Active, not recruiting
2
163
Europe, US, RoW
TAR-200, JNJ-17000139, Cetrelimab, JNJ-63723283
Janssen Research & Development, LLC, Janssen Research & Development LLC
Urinary Bladder Neoplasms
02/25
03/27
NCT04926181: Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Active, not recruiting
2
2
US
Apalutamide, Erleada, Androgen Receptor Inhibitorsv(ARI), Apalutamide Oral Tablet, Cetrelimab, JNJ-63723283, Anti-PD-1 antibody cetrelimab (JNJ-63723283), CET
Rahul Aggarwal, Janssen Scientific Affairs, LLC
Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma
03/24
02/25
NCT06534190: CD8 PET Imaging in Metastatic Solid Tumours

Recruiting
2
30
Europe
89Zr-Df-crefmirlimab PET scan, Nivolumab, Cetrelimab, zirconium Zr 89 crefmirlimab berdoxam, Zr-89 crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C
University Medical Center Groningen
Locally Advanced Solid Tumor
11/28
11/28
NCT04592237: Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Active, not recruiting
2
120
US
Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cetrelimab, JNJ 63723283, JNJ-63723283, JNJ63723283, WHO 10757, Niraparib, MK-4827, MK4827
M.D. Anderson Cancer Center, Janssen Pharmaceutica
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8
12/25
12/25
SunRISe-1, NCT04640623 / 2020-002646-16: A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

Active, not recruiting
2
220
Europe, Canada, Japan, US, RoW
TAR-200, JNJ-17000139, Gemcitabine-Releasing Intravesical System, Cetrelimab, JNJ-63723283
Janssen Research & Development, LLC, Janssen Research & Development LLC
Urinary Bladder Neoplasms
11/26
07/27
QUEST, NCT03431350 / 2017-003552-23: A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
1/2
136
Europe, Canada, US, RoW
Niraparib 200 mg, Cetrelimab 240 mg, JNJ-63723283, Cetrelimab 480 mg, Abiraterone acetate 1000 mg, Prednisone 5 mg
Janssen Research & Development, LLC
Prostatic Neoplasms, Castration-Resistant
08/21
12/25
NORSE, NCT03473743 / 2017-001980-19: A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Checkmark Presenation of data from NORSE trial in combination with cetrelimab for 2L metastatic urothelial carcinoma at ESMO 2021
Sep 2021 - Sep 2021: Presenation of data from NORSE trial in combination with cetrelimab for 2L metastatic urothelial carcinoma at ESMO 2021
Checkmark Presenation of data from NORSE trial in combination with BALVERSA for 2L metastatic urothelial carcinoma at ESMO 2021
Sep 2021 - Sep 2021: Presenation of data from NORSE trial in combination with BALVERSA for 2L metastatic urothelial carcinoma at ESMO 2021
Active, not recruiting
1/2
125
Europe, US, RoW
Erdafitinib, JNJ-42756493, Cetrelimab, JNJ-63723283, Cisplatin, Carboplatin
Janssen Research & Development, LLC
Urothelial Carcinoma
09/22
12/25
NCT02908906 / 2016-002017-22: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Active, not recruiting
1/2
413
Europe, US, RoW
JNJ-63723283, Cetrelimab
Janssen Research & Development, LLC
Neoplasms
11/23
10/25
PolyDamas, NCT05908734: A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

Recruiting
1/2
75
Europe, US, RoW
Cetrelimab, JNJ-63723283, Amivantamab, JNJ-61186372
Janssen Research & Development, LLC
Carcinoma, Non-Small-Cell Lung
06/25
06/26
NCT05242445: A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection

Completed
1
11
Europe
Cetrelimab, JNJ-63723283, Placebo
Janssen Research & Development, LLC
Hepatitis B, Chronic
05/23
05/23
NCT06311578: A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

Recruiting
1
96
Europe, US
JNJ-87704916, Cetrelimab, JNJ-63723283
Johnson & Johnson Enterprise Innovation Inc.
Advanced Solid Tumors
11/28
11/33
NCT05818683: A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer

Recruiting
1
200
US, RoW
JNJ-78278343, Cetrelimab, JNJ-63723283, Cabazitaxel, Docetaxel, Apalutamide, Enzalutamide, Darolutamide, Abiraterone acetate plus prednisone (AAP)
Janssen Research & Development, LLC
Metastatic Castration-resistant Prostate Neoplasms
06/25
09/27
NCT06116786: A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

Recruiting
1
126
Europe, US, RoW
JNJ-86974680, Cetrelimab, Radiation Therapy
Johnson & Johnson Enterprise Innovation Inc.
Carcinoma, Non-small-Cell Lung
04/27
06/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cetrelimab (JNJ-63723283) / J&J
2020-004506-64: A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)

Ongoing
3
1050
Europe
TAR-200, Cetrelimab, Vesiculture, JNJ-17000139, JNJ-63723283, Tablet, Powder for solution for infusion, Powder for bladder irrigation, Vesiculture, powder for bladder irrigation
Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & development LLC, Janssen Research & Development LLC, Janssen-Cilag SpA, Janssen-cilag international NV
BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer, Bladder cancer, Diseases [C] - Cancer [C04]
 
 
SunRISe-2, NCT04658862 / 2020-002620-36: A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

Active, not recruiting
3
518
Europe, Canada, Japan, US, RoW
Cetrelimab, JNJ-63723283, TAR-200, JNJ-17000139, Cisplatin, Gemcitabine, Conventional radiation therapy, Hypo-fractioned radiation therapy
Janssen Research & Development, LLC, Janssen Research & Development LLC
Urinary Bladder Neoplasms
12/26
12/29
SunRISe-3, NCT05714202 / 2020-004506-64: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

Active, not recruiting
3
1135
Europe, Canada, Japan, US, RoW
TAR-200, JNJ-17000139, Cetrelimab, JNJ-63723283, BCG Vesiculture
Janssen Research & Development, LLC, Janssen Research & development LLC, Janssen Research & Development LLC, Janssen-Cilag SpA, Janssen-cilag international NV
Bladder Cancer
09/29
09/29
2020-005565-13: A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy Estudio de fase 2, multicéntrico, aleatorizado y abierto, de TAR-200 en combinación con cetrelimab y monoterapia con cetrelimab en participantes con carcinoma urotelial de vejiga músculo-invasivo que se vayan a tratar con cistectomía radical y no sean elegibles o rechacen recibir tratamiento con quimioterapia neoadyuvante basada en platino

Ongoing
2
160
Europe
TAR-200, Cetrelimab, JNJ-17000139, JNJ-63723283, Tablet, Lyophilisate for solution for infusion
Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development LLC
Muscle-Invasive Urothelial Carcinoma of the Bladder Carcinoma urotelial de vejiga músculo-invasivo, Bladder cancer Cáncer de vejiga, Diseases [C] - Cancer [C04]
 
 
2022-002586-15: Erdafitinib (ERDA) alone or in combination with cetrelimab (CET) as neoadjuvant treatment (prior to surgery) in subjects with muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations and are ineligible for receiving cisplatin treatment Erdafitinib (ERDA) solo o en combinación con cetrelimab (CET) como tratamiento neoadyuvante (antes de la cirugía) en sujetos con cáncer de vejiga músculo-invasivo cuyos tumores expresan alteraciones del gen FGFR y no son elegibles para recibir tratamiento con cisplatino

Not yet recruiting
2
90
Europe
Cetrelimab, Erdafitinib, JNJ-63723283, JNJ-42756493, Solution for infusion, Tablet, Balversa
Spanish Oncology Genito Urinary Group (SOGUG), Spanish Oncology Genitourinary Group (SOGUG), Janssen Pharmaceutica NV
Muscle-invasive bladder cancer (MIBC) Cáncer de vejiga con invasión muscular, Bladder cancer that spreads beyond the inner lining of the bladder and into the muscle layer Cáncer de vejiga que se propaga al musculo grueso, Diseases [C] - Cancer [C04]
 
 
SOGUG-NEOWIN, NCT06511648 / 2022-002586-15: Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Recruiting
2
90
Europe
Erdafitinib monotherapy, Cetrelimab and Erdafitinib combination
Spanish Oncology Genito-Urinary Group, Janssen-Cilag Ltd., Pivotal S.L.
Muscle-invasive Bladder Cancer
03/26
03/29
SunRISe-4, NCT04919512 / 2020-005565-13: A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

Active, not recruiting
2
163
Europe, US, RoW
TAR-200, JNJ-17000139, Cetrelimab, JNJ-63723283
Janssen Research & Development, LLC, Janssen Research & Development LLC
Urinary Bladder Neoplasms
02/25
03/27
NCT04926181: Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Active, not recruiting
2
2
US
Apalutamide, Erleada, Androgen Receptor Inhibitorsv(ARI), Apalutamide Oral Tablet, Cetrelimab, JNJ-63723283, Anti-PD-1 antibody cetrelimab (JNJ-63723283), CET
Rahul Aggarwal, Janssen Scientific Affairs, LLC
Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma
03/24
02/25
NCT06534190: CD8 PET Imaging in Metastatic Solid Tumours

Recruiting
2
30
Europe
89Zr-Df-crefmirlimab PET scan, Nivolumab, Cetrelimab, zirconium Zr 89 crefmirlimab berdoxam, Zr-89 crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C
University Medical Center Groningen
Locally Advanced Solid Tumor
11/28
11/28
NCT04592237: Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Active, not recruiting
2
120
US
Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cetrelimab, JNJ 63723283, JNJ-63723283, JNJ63723283, WHO 10757, Niraparib, MK-4827, MK4827
M.D. Anderson Cancer Center, Janssen Pharmaceutica
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8
12/25
12/25
SunRISe-1, NCT04640623 / 2020-002646-16: A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

Active, not recruiting
2
220
Europe, Canada, Japan, US, RoW
TAR-200, JNJ-17000139, Gemcitabine-Releasing Intravesical System, Cetrelimab, JNJ-63723283
Janssen Research & Development, LLC, Janssen Research & Development LLC
Urinary Bladder Neoplasms
11/26
07/27
QUEST, NCT03431350 / 2017-003552-23: A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
1/2
136
Europe, Canada, US, RoW
Niraparib 200 mg, Cetrelimab 240 mg, JNJ-63723283, Cetrelimab 480 mg, Abiraterone acetate 1000 mg, Prednisone 5 mg
Janssen Research & Development, LLC
Prostatic Neoplasms, Castration-Resistant
08/21
12/25
NORSE, NCT03473743 / 2017-001980-19: A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Checkmark Presenation of data from NORSE trial in combination with cetrelimab for 2L metastatic urothelial carcinoma at ESMO 2021
Sep 2021 - Sep 2021: Presenation of data from NORSE trial in combination with cetrelimab for 2L metastatic urothelial carcinoma at ESMO 2021
Checkmark Presenation of data from NORSE trial in combination with BALVERSA for 2L metastatic urothelial carcinoma at ESMO 2021
Sep 2021 - Sep 2021: Presenation of data from NORSE trial in combination with BALVERSA for 2L metastatic urothelial carcinoma at ESMO 2021
Active, not recruiting
1/2
125
Europe, US, RoW
Erdafitinib, JNJ-42756493, Cetrelimab, JNJ-63723283, Cisplatin, Carboplatin
Janssen Research & Development, LLC
Urothelial Carcinoma
09/22
12/25
NCT02908906 / 2016-002017-22: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Active, not recruiting
1/2
413
Europe, US, RoW
JNJ-63723283, Cetrelimab
Janssen Research & Development, LLC
Neoplasms
11/23
10/25
PolyDamas, NCT05908734: A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

Recruiting
1/2
75
Europe, US, RoW
Cetrelimab, JNJ-63723283, Amivantamab, JNJ-61186372
Janssen Research & Development, LLC
Carcinoma, Non-Small-Cell Lung
06/25
06/26
NCT05242445: A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection

Completed
1
11
Europe
Cetrelimab, JNJ-63723283, Placebo
Janssen Research & Development, LLC
Hepatitis B, Chronic
05/23
05/23
NCT06311578: A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

Recruiting
1
96
Europe, US
JNJ-87704916, Cetrelimab, JNJ-63723283
Johnson & Johnson Enterprise Innovation Inc.
Advanced Solid Tumors
11/28
11/33
NCT05818683: A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer

Recruiting
1
200
US, RoW
JNJ-78278343, Cetrelimab, JNJ-63723283, Cabazitaxel, Docetaxel, Apalutamide, Enzalutamide, Darolutamide, Abiraterone acetate plus prednisone (AAP)
Janssen Research & Development, LLC
Metastatic Castration-resistant Prostate Neoplasms
06/25
09/27
NCT06116786: A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

Recruiting
1
126
Europe, US, RoW
JNJ-86974680, Cetrelimab, Radiation Therapy
Johnson & Johnson Enterprise Innovation Inc.
Carcinoma, Non-small-Cell Lung
04/27
06/29

Download Options